News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

Opinion|Videos|August 28, 2024

Early Diagnosis and Treatment for Central Precocious Puberty

Author(s)Karen O. Klein, MD, Jill Samis, MD , Aviva B. Sopher, MD, MS

The panel explores the impact of early versus delayed diagnosis and treatment initiation on long-term outcomes in Central Precocious Puberty patients.

Episodes in this series

3 KOLs are featured in this series.

EP. 1 Overview Of Central Precocious Puberty

3 KOLs are featured in this series.

EP. 2 Diagnosis of Central Precocious Puberty and its Psychosocial Impact

3 KOLs are featured in this series.

EP. 3 Early Diagnosis and Treatment for Central Precocious Puberty

3 KOLs are featured in this series.

EP. 4 Treatment Options for Central Precocious Puberty

3 KOLs are featured in this series.

EP. 5 Safety and Efficacy of GnRHa Treatments in Central Precocious Puberty

3 KOLs are featured in this series.

EP. 6 Individualized Management of Central Precocious Puberty

3 KOLs are featured in this series.

EP. 7 Central Precocious Puberty Treatment Starts, Discontinuations and Misconceptions

3 KOLs are featured in this series.

EP. 8 Central Precocious Puberty in Male Patients

3 KOLs are featured in this series.

EP. 9 Recommendations and Outlook for Central Precocious Puberty

Video content above is prompted by the following:

How might an early CPP diagnosis and subsequent treatment initiation affect outcomes, compared to a later start?

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

FAQ: Which children with early puberty actually need testing and treatment?

Researchers identify hypermobility-linked autonomic subtype of eosinophilic esophagitis in children

FDA clears IND for investigational SUMF1 gene therapy in multiple sulfatase deficiency

FDA accepts roflumilast sNDA for AD in infants aged 3 to 24 months

FDA accepts deucrictibant IR application for on-demand treatment of hereditary angioedema attacks